by stemedica admin | May 13, 2016 | Publications
ABSTRACT Developing effective therapies for heart failure (HF) is challenging. Despite several clear successes in the development and delivery of pharmacotherapies for ambulatory patients with HF and reduced ejection fraction (HFrEF), efforts to modulate adverse...
by stemedica admin | Nov 3, 2015 | Publications
Abstract Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular disease. Although encouraging outcome signals have been reported, these have been small, leading to uncertainty as to whether they will translate into...
by stemedica admin | Aug 13, 2015 | Intellectual Property
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” The patent issued on July...
by stemedica admin | Jun 9, 2015 | Intellectual Property
Stemedica Cell Technologies Inc., a leading manufacturer of adult, allogeneic stem cells and stem cell factors, received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.” This patent, coupled with the US8105380 patent...
by stemedica admin | Mar 24, 2015 | Partnerships
Commercial-scale Preservation of Therapeutically-active Stem Cell-derived Products For Worldwide Marketplace Opportunities SAN DIEGO—March 24, 2015—Stemedica Cell Technologies Inc., (Stemedica), announced today that Universal Stabilization Technologies (UST) has...
